In GlobalData’s Clinical Trials Database, there are currently 1,490 active clinical trials for in vitro diagnostics (IVD) devices, where 569 trials are focused on oncology diagnostic devices. Specifically, nine of these trials involve analysis or partial analysis. This month, Mindpeak, an artificial intelligence (AI) solution and software provider, and Proscia, a computational and digital pathology solutions company, partnered to improve cancer diagnosis. The partnership will streamline pathologists’ workflows with AI to make more efficient clinical decisions from digital pathology images of patient samples. The goal of this partnership is to use Mindpeak’s breast cancer detection software, BreastIHC, and Proscia’s open digital pathology platform, Concentriq Dx, to better diagnose breast cancer through digital pathology analysis with AI.

Additionally, an active trial named Artificial Intelligence Neuropathologist by Huashan Hospital and United Imaging Healthcare is currently testing their AI’s ability to detect central nervous system (CNS) tumours unsupervised and fully automated. This will aid in individuals getting treated faster as the device analyzes and processes samples quicker than physicians and improves diagnosis accuracy. The goal of this trial is to develop a self-learning AI-led device that will be able to provide a clinical pathological diagnosis ability with an accuracy of 90% or greater.

With these ground-breaking devices in the pipeline, GlobalData predicts that in the next decade, more IVD manufacturers will adopt AI tech into their devices to improve diagnostic and treatment predictions and oncologists’ workflow. Therefore, more individuals will receive life-saving interventions in earlier stages of cancer and treatments that have been shown to be the most effective by AI.